Logo image of MNPR

MONOPAR THERAPEUTICS INC (MNPR) Stock Fundamental Analysis

NASDAQ:MNPR - Nasdaq - US61023L2079 - Common Stock - Currency: USD

36.9  +1.31 (+3.68%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNPR. MNPR was compared to 558 industry peers in the Biotechnology industry. While MNPR has a great health rating, there are worries on its profitability. MNPR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MNPR has reported negative net income.
In the past year MNPR has reported a negative cash flow from operations.
MNPR had negative earnings in each of the past 5 years.
MNPR had a negative operating cash flow in each of the past 5 years.
MNPR Yearly Net Income VS EBIT VS OCF VS FCFMNPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

With a decent Return On Assets value of -30.08%, MNPR is doing good in the industry, outperforming 66.49% of the companies in the same industry.
MNPR's Return On Equity of -30.92% is fine compared to the rest of the industry. MNPR outperforms 76.70% of its industry peers.
Industry RankSector Rank
ROA -30.08%
ROE -30.92%
ROIC N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
MNPR Yearly ROA, ROE, ROICMNPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNPR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNPR Yearly Profit, Operating, Gross MarginsMNPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

9

2. Health

2.1 Basic Checks

MNPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MNPR has been reduced compared to 5 years ago.
There is no outstanding debt for MNPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MNPR Yearly Shares OutstandingMNPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MNPR Yearly Total Debt VS Total AssetsMNPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 85.71 indicates that MNPR is not in any danger for bankruptcy at the moment.
MNPR has a better Altman-Z score (85.71) than 98.92% of its industry peers.
There is no outstanding debt for MNPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 85.71
ROIC/WACCN/A
WACCN/A
MNPR Yearly LT Debt VS Equity VS FCFMNPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 36.91 indicates that MNPR has no problem at all paying its short term obligations.
MNPR has a better Current ratio (36.91) than 98.39% of its industry peers.
A Quick Ratio of 36.91 indicates that MNPR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 36.91, MNPR belongs to the top of the industry, outperforming 98.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 36.91
Quick Ratio 36.91
MNPR Yearly Current Assets VS Current LiabilitesMNPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for MNPR have decreased strongly by -53.85% in the last year.
EPS 1Y (TTM)-53.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

MNPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.57% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y40.7%
EPS Next 2Y13.03%
EPS Next 3Y8.75%
EPS Next 5Y21.57%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNPR Yearly Revenue VS EstimatesMNPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
MNPR Yearly EPS VS EstimatesMNPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MNPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNPR Price Earnings VS Forward Price EarningsMNPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNPR Per share dataMNPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.03%
EPS Next 3Y8.75%

More info and screens

0

5. Dividend

5.1 Amount

MNPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MONOPAR THERAPEUTICS INC

NASDAQ:MNPR (6/5/2025, 12:05:43 PM)

36.9

+1.31 (+3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-07 2025-08-07
Inst Owners45.53%
Inst Owner Change11.89%
Ins Owners6.62%
Ins Owner Change-2.09%
Market Cap225.83M
Analysts80
Price Target59.84 (62.17%)
Short Float %0.95%
Short Ratio1.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-248.35%
Min EPS beat(2)-541.92%
Max EPS beat(2)45.21%
EPS beat(4)2
Avg EPS beat(4)-119.46%
Min EPS beat(4)-541.92%
Max EPS beat(4)45.21%
EPS beat(8)6
Avg EPS beat(8)-50.18%
EPS beat(12)8
Avg EPS beat(12)-32.11%
EPS beat(16)11
Avg EPS beat(16)-22.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)26.16%
EPS NQ rev (1m)3.86%
EPS NQ rev (3m)14.83%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.21
P/tB 4.21
EV/EBITDA N/A
EPS(TTM)-4
EYN/A
EPS(NY)-2.2
Fwd EYN/A
FCF(TTM)-1.7
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS8.76
TBVpS8.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.08%
ROE -30.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.42%
ROA(5y)-61.44%
ROE(3y)-100.89%
ROE(5y)-75.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 36.91
Quick Ratio 36.91
Altman-Z 85.71
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24%
EPS Next Y40.7%
EPS Next 2Y13.03%
EPS Next 3Y8.75%
EPS Next 5Y21.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.64%
OCF growth 3YN/A
OCF growth 5YN/A